Related Experiment Video
Updated: Mar 28, 2026

08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
16.8K
Primary cutaneous and subcutaneous leiomyosarcomas: evolution and prognostic factors
Jose Aneiros-Fernandez1, Juan Antonio Retamero1, Husein Husein-Elahmed1
1Department of Pathology, Complejos Universitario Hospitalario de Granada, Avd. Madrid S/N, 18012 Granada, Spain.
European Journal of Dermatology : EJD
|December 19, 2015
Summary
Cutaneous and subcutaneous leiomyosarcomas (LMS) are rare tumors. Subcutaneous LMS have higher recurrence, metastasis, and mortality rates than cutaneous LMS, necessitating distinct management and follow-up.
Area of Science:
- Oncology
- Dermatology
- Surgical Pathology
Background:
- Cutaneous and subcutaneous leiomyosarcomas (LMS) are infrequent malignant neoplasms.
- Understanding their distinct prognostic factors and behavior is crucial for patient management.
Purpose of the Study:
- To review and compare recurrence, metastasis, and mortality rates of cutaneous and subcutaneous LMS.
- To identify prognostic factors and recommend appropriate follow-up periods for these rare tumors.
Main Methods:
- A comprehensive review of the MEDLINE database was conducted.
- Data from 112 subcutaneous LMS and 313 cutaneous LMS cases were analyzed.
- Recurrence, metastasis, mortality rates, and prognostic factors were assessed.
Main Results:
- Subcutaneous LMS exhibited higher rates of recurrence (36.63%), metastasis (43.23%), and mortality (37.82%) compared to cutaneous LMS (24.40%, 4.22%, 3.33%, respectively).
- Location, size, and histologic grade are significant prognostic factors for superficial LMS.
- Complete excision with at least a 1 cm surgical margin is recommended to prevent recurrence.
Conclusions:
- Cutaneous and subcutaneous LMS, despite similar morphology, demonstrate significantly different clinical behaviors.
- Subcutaneous LMS present a greater risk of adverse outcomes, warranting prolonged surveillance.
- A minimum five-year follow-up is recommended for both types of LMS.
Related Concept Videos
Tumor Progression
7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Tumor Progression
3.5K
3.5K
Skin Cancer
6.6K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.6K
Cancer Survival Analysis
827
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
827

